Calendar Opportunities Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar with AI-powered predictions. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Real-time alerts for biotech investors.

Quick Links

This Week's Catalysts
Full Calendar
Catalyst Types
Search Companies
Biotech Glossary
Embed Widget

Legal

About
ML Track Record
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

⚠️ Not Financial Advice (NFA)

CatalystAlert provides data aggregation and analysis tools only. All probability scores and predictions are based on historical data and are NOT guarantees of future results. Past performance does not indicate future success. We are not responsible for the accuracy of third-party data sources. Always consult a qualified financial advisor before making investment decisions.

© 2025 CatalystAlert. All rights reserved.

Data may be delayed or incomplete. Use at your own risk.

1.5 mg RPL554 plus tiotropium - Phase 2 | VRNA Pipeline | CatalystAlert

1.5 mg RPL554 plus tiotropium

Phase 2

VERONA PHARMA (VRNA)

Phase 2

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease Moderate

Clinical Trial

Last updated: 12/13/2025

Developer

VRNA

VERONA PHARMA

Healthcare•North America•NASDAQ

Related Pipeline

EnsifentrinePhase 3

Chronic Obstructive Pulmonary Disease

Ensifentrine 3 mg twice dailyPhase 3

COPD

RPL554 suspensionPhase 2

COPD

Part A: RPL554Phase 2

Pulmonary Disease, Chronic Obstructive

Nebulized Ensifentrine Suspension; 3 mgPhase 2

Non-cystic Fibrosis Bronchiectasis

View full pipeline